Every material Form 8-K Alto Neuroscience, Inc. has filed with the SEC since July 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Alto Neuroscience promoted Chief Financial Officer and Chief Business Officer Nicholas C. Smith to President and Chief Financial Officer effective August 26, 2026. CEO Amit Etkin remains chief executive but no longer holds the title of President. Smith's promotion comes with a $6 million cash retention agreement, which he forfeits if he leaves or is terminated for Cause before the two-year anniversary.
Nicholas C. Smith named President and Chief Financial Officer, effective August 26, 2026
Amit Etkin, M.D., Ph.D. continues as Chief Executive Officer and is no longer President
Retention Payment totals $6,000,000: $3,000,000 within ten days of the Effective Date and $3,000,000 at the twelve-month anniversary
Unpaid portion is forfeited and paid amounts may be recouped if Smith leaves before the two-year anniversary
Alto Neuroscience reported a second-quarter 2026 net loss of $27.6 million, up from $17.7 million a year earlier, as research and development spending rose to $22.1 million from $13.1 million. The company said it had about $338 million in pro forma cash after a July 2026 offering, which it expects to fund planned operations through 2030, and it added a Phase 3 monotherapy trial of ALTO-207 to its development plan.
Q2 2026 net loss was $27.6 million, versus $17.7 million in Q2 2025; net loss per share was $0.65 in both periods.
R&D expenses were $22.1 million versus $13.1 million; G&A expenses were $7.0 million versus $5.6 million.
Cash, cash equivalents, and restricted cash were $244.2 million at June 30, 2026, versus $177.0 million at December 31, 2025.
July 2026 registered direct offering raised gross proceeds of about $100.0 million; pro forma cash is about $338 million.
Alto Neuroscience entered into an underwriting agreement on July 13, 2026, to sell 3,776,436 shares of common stock at $26.48 per share in a registered direct offering, with estimated net proceeds of approximately $93.9 million. The company plans to use the proceeds with its existing cash to accelerate ALTO-207 development, including an additional planned Phase 3 trial in treatment-resistant depression. The sale adds new shares outstanding, which dilutes existing holders, and closing is expected July 14, 2026.
Shares offered: 3,776,436 common shares at $26.48 each
Estimated net proceeds: approximately $93.9 million, after underwriting discounts and offering expenses
Use of proceeds: ALTO-207 clinical development, including an additional Phase 3 trial in treatment-resistant depression, and general working capital
Expected closing: July 14, 2026, subject to customary conditions; BofA Securities is representative
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Alto Neuroscience, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →